Skip to main content

Advertisement

Log in

Chemotherapy response assessment in stage IV melanoma patients—comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

This study aims to compare the use of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B in chemotherapy response assessment of stage IV melanoma patients.

Methods

In 25 patients with stage IV melanoma, FDG-PET/CT and S-100B after 2–3 months (three cycles) of chemotherapy was compared with baseline PET/CT and baseline S-100B. Retrospectively, the response was correlated with the outcome. In patients with clinical suspicion for brain metastases, MRI or CCT was performed.

Results

There was agreement between FDG-PET/CT and CT regarding response to chemotherapy in all patients. There was a clear trend to a longer OS of PET/CT responders (n = 10) compared with PET/CT non-responders (n = 15; p = 0.072) with remarkably better 1-year OS of 80% compared to 40% (p = 0.048). There was a significant longer PFS of PET/CT responders compared with PET/CT non-responders (p = 0.002). S-100B was normal at baseline in eight of 22 patients where it was available. Chemotherapy response assessment with S-100B failed to show correlation with OS or PFS. Eleven patients developed brain metastases during treatment, first detected by PET/CT in two and by MRI or CCT in nine of 11 patients. Appearance of brain metastases was associated with a poor survival.

Conclusions

18F-FDG-PET/CT and CT alone are equally suitable for chemotherapy response assessment in melanoma patients and clearly superior to S-100B. PET/CT responders have better early survival, but this is shortlived due to late therapy failure—often with brain recurrence. Additional brain MRI for therapy response assessment in such high-risk patients is mandatory to detect brain metastases missed by PET/CT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748–59.

    Article  PubMed  CAS  Google Scholar 

  2. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201.

    PubMed  CAS  Google Scholar 

  3. Schadendorf D. Is there a standard for the palliative treatment of melanoma. Onkologie 2002;25:74–6.

    Article  PubMed  CAS  Google Scholar 

  4. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res. 1999;9:51–8.

    Article  PubMed  CAS  Google Scholar 

  5. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178–87.

    Article  PubMed  Google Scholar 

  6. Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007;244:566–74.

    Article  PubMed  Google Scholar 

  7. Strobel K, Skalsky J, Kalff V, et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging. 2007;34:1366–75.

    Article  PubMed  Google Scholar 

  8. Dalrymple-Hay MJ, Rome PD, Kennedy C, Fulham M, McCaughan BC. Pulmonary metastatic melanoma–the survival benefit associated with positron emission tomography scanning. Eur J Cardiothorac Surg. 2002;21:611–4, discussion 614–615.

    Article  PubMed  CAS  Google Scholar 

  9. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol. 2005;23:4577–80.

    Article  PubMed  Google Scholar 

  10. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.

    Article  PubMed  CAS  Google Scholar 

  11. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med. 2005;35:186–96.

    Article  PubMed  Google Scholar 

  12. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–8.

    Article  PubMed  Google Scholar 

  13. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797–805.

    Article  PubMed  Google Scholar 

  14. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8362–70.

    Article  PubMed  Google Scholar 

  15. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144–50.

    PubMed  Google Scholar 

  16. Strobel K, Skalsky J, Steinert HC, et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology 2007;215:192–201.

    Article  PubMed  CAS  Google Scholar 

  17. Ryan ER, Hill AD, Skehan SJ. FDG PET/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma. Clin Nucl Med. 2006;31:707–8.

    Article  PubMed  Google Scholar 

  18. Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol. 1997;137:381–5.

    Article  PubMed  CAS  Google Scholar 

  19. Andres R, Mayordomo JI, Zaballos P, et al. Prognostic value of serum S-100B in malignant melanoma. Tumori 2004;90:607–10.

    PubMed  CAS  Google Scholar 

  20. Banfalvi T, Gilde K, Boldizsar M, Kremmer T, Otto S. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. Pathol Oncol Res. 1999;5:218–22.

    Article  PubMed  CAS  Google Scholar 

  21. Domingo-Domenech J, Molina R, Castel T, et al. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon—comparison with tyrosinase rt-PCR. Oncology 2005;68:341–9.

    Article  PubMed  CAS  Google Scholar 

  22. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:1898–902.

    Article  PubMed  CAS  Google Scholar 

  23. Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003;13:45–9.

    Article  PubMed  CAS  Google Scholar 

  24. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.

    PubMed  Google Scholar 

  25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  26. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003;226:181–7.

    Article  PubMed  Google Scholar 

  27. Holtas S, Cronqvist S. Cranial computed tomography of patients with malignant melanoma. Neuroradiology 1981;22:123–7.

    PubMed  CAS  Google Scholar 

  28. Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G. Serum S100–a marker for disease monitoring in metastatic melanoma. Dermatology 1997;194:208–12.

    Article  PubMed  CAS  Google Scholar 

  29. Hauschild A, Engel G, Brenner W, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol. 1999;140:1065–71.

    Article  PubMed  CAS  Google Scholar 

  30. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference. J Nucl Med. 2007;48(Suppl 1):36S–44S.

    PubMed  CAS  Google Scholar 

  31. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–9.

    Article  PubMed  CAS  Google Scholar 

  32. de Geus-Oei LF, van der Heijden HF, Visser EP, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007;48:1592–8.

    Article  PubMed  Google Scholar 

  33. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626–32.

    Article  PubMed  Google Scholar 

  34. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.

    Article  PubMed  Google Scholar 

  35. Majer M, Jensen RL, Shrieve DC, et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 2007;110:1329–37.

    Article  PubMed  CAS  Google Scholar 

  36. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293–300.

    Article  PubMed  CAS  Google Scholar 

  37. Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur J Cancer. 1978;14:327–30.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Klaus Strobel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strobel, K., Dummer, R., Steinert, H.C. et al. Chemotherapy response assessment in stage IV melanoma patients—comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging 35, 1786–1795 (2008). https://doi.org/10.1007/s00259-008-0806-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-008-0806-1

Keywords

Navigation